PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930060
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930060
The global softgel capsules market was valued at USD 7.87 billion in 2025 and is projected to reach USD 8.32 billion in 2026, ultimately expanding to USD 13.44 billion by 2034, reflecting a CAGR of 6.18% during the forecast period. North America dominated the market in 2025 with a 35.60% share, driven by rising clinical trials, strong R&D infrastructure, and a high presence of key pharmaceutical manufacturers. The U.S. market is projected to reach USD 3.92 billion by 2032, supported by the growing number of clinical studies promoting the usage of softgel capsules for chronic ailments. Key players include Capsugel (Lonza), Catalent, Inc., Sirio Pharma, and Aenova Holding GmbH, focusing on product innovation and market expansion.
Softgel capsules are oral dosage forms containing a semi-solid or liquid core encapsulated within gelatin, opacifiers, and plasticizers such as sorbitol or glycerin. These capsules offer enhanced bioavailability, stability, and solubility, making them suitable for pharmaceuticals, nutraceuticals, and dietary supplements. Increasing awareness of preventive healthcare, rising prevalence of chronic diseases such as cardiovascular disorders, and a growing geriatric population are major factors driving the global softgel capsules market.
Market Drivers
Rising Clinical Trials and Product Launches: The increasing number of clinical studies evaluating softgel capsules for treating chronic diseases is a key growth driver. For example, in August 2021, InnoPharmax Inc. sponsored trials to assess softgel combinations for biliary tract cancer treatment. Product innovations by key players such as Catalent's OptiGel DR technology, enabling delayed or enteric-release capsules, further support market expansion.
Demand for Plant-Based Capsules: Vegetarian or vegan softgel capsules are gaining popularity due to their natural, non-animal composition, absence of gluten, GMO-free status, and improved solubility. These capsules are viewed as safer and more effective by consumers, particularly in Europe, North America, and Asia Pacific, creating opportunities for new product lines and market differentiation.
Health & Dietary Supplements Growth: In 2026, the health & dietary supplements segment accounted for 57.23% share, driven by the growing need for vitamins and supplements to prevent chronic diseases, including cardiovascular conditions and age-related health issues. Prescription medicines in softgel form are also witnessing significant growth, supported by chronic disease prevalence and regulatory approvals for generic and innovative formulations.
Market Restraints
Patent Expirations and Generic Competition: Loss of patent exclusivity for leading drugs may negatively impact pharmaceutical companies' revenues, introducing generic competition. This could influence market dynamics and affect growth potential for proprietary softgel products.
Market Segmentation
By Type: The market is segmented into gelatin capsules and non-animal softgel capsules. In 2026, gelatin capsules held the largest market share at 85.21%, driven by robust R&D investments, high production capacity, and established manufacturing processes. The non-animal segment, including cellulose-based and pullulan capsules, is growing steadily due to rising demand for vegan-friendly options.
By Manufacturer: Pharmaceutical companies dominate with 57.04% share in 2026, supported by large-scale production and extensive R&D investments. Nutraceutical companies also contribute significantly, benefiting from the global rise in dietary supplement launches.
By Region:
Competitive Landscape
The global market is moderately consolidated, with Capsugel (Lonza) and Catalent, Inc. leading in revenue and product innovation. Key industry developments include the launch of Amneal Pharmaceuticals' Icosapent ethyl softgel in December 2023 and Roquette's LYCAGEL PREMIX in November 2021. Companies are focusing on expanding geographic presence, pipeline development, and advanced manufacturing technologies.
Conclusion
The global softgel capsules market is expected to grow from USD 7.87 billion in 2025 to USD 13.44 billion by 2034, driven by rising clinical trials, growing chronic disease prevalence, demand for plant-based capsules, and increasing adoption of dietary supplements. North America leads the market, while Asia Pacific is poised for the fastest growth. Gelatin capsules dominate, supported by R&D and manufacturing capacities, whereas non-animal capsules are gaining traction due to consumer preference. The market outlook remains strong as key players focus on innovation, regulatory approvals, and global expansion, ensuring sustained growth and enhanced product availability worldwide.
Segmentation By Type
By Application
By Manufacturers
By Region